文献速递妇科

美国镭学会®子宫癌肉瘤管理适当使用标准执行摘要

Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.
PubMed 文献 · Gynecol Oncol · 2020-05-29

美国镭学会®基于文献分析与改良德尔菲法制定子宫癌肉瘤管理适当使用标准,由多学科专家组针对影像与治疗流程进行适当性评级;多数患者初诊即为晚期宫外病变,10%有转移,非转移者以完整手术分期为主,辅助多模式治疗可能减少复发并改善总生存。

要点

  • 子宫癌肉瘤患者多数初诊即为晚期宫外病变,10%初诊时已有转移。
  • 非转移性子宫癌肉瘤的主要治疗为完整手术分期,包括全子宫切除、输卵管卵巢切除及淋巴结分期。
  • 早期与晚期患者均可考虑辅助多模式治疗以减少复发,并可能改善总生存。

核心结论

  • 诊断为子宫癌肉瘤的女性应接受完整手术分期。
  • 早期和晚期患者均应考虑辅助多模式治疗。
  • 由于许多患者可能复发,需长期监测。
  • 需对子宫癌肉瘤患者开展前瞻性临床研究以实现最佳管理。

研究设计与样本

  • 美国镭学会®适当使用标准由多学科专家组基于同行评议期刊文献的广泛分析制定。
  • 采用改良德尔菲法对子宫癌肉瘤管理的影像与治疗流程进行适当性评级。

主要发现

  • 子宫癌肉瘤占子宫恶性肿瘤不足5%,为罕见但侵袭性强的子宫内膜癌亚型。
  • 多数子宫癌肉瘤患者初诊即为晚期宫外病变,10%初诊时有转移。
  • 与子宫高级别子宫内膜样腺癌相比,子宫癌肉瘤患者生存结局更差。
  • 非转移性子宫癌肉瘤的主要治疗为完整手术分期,包括全子宫切除、输卵管卵巢切除及淋巴结分期。
  • 子宫癌肉瘤患者似乎可从辅助多模式治疗中获益,以降低肿瘤复发风险并可能改善总生存。

关键数值与推荐

  • 诊断为子宫癌肉瘤的女性应接受完整手术分期。
  • 早期和晚期子宫癌肉瘤患者均应考虑辅助多模式治疗。
  • 子宫癌肉瘤患者需长期监测,因许多患者可能复发。

临床怎么用

  • 对子宫癌肉瘤患者行完整手术分期,包括全子宫切除、输卵管卵巢切除及淋巴结分期。
  • 对早期和晚期子宫癌肉瘤患者考虑辅助多模式治疗。
  • 对子宫癌肉瘤患者进行长期监测。

局限性

  • 原文指出针对这一罕见恶性肿瘤,迄今仅有有限的前瞻性试验可用于制定循证管理。
  • 原文结论指出需对子宫癌肉瘤患者开展前瞻性临床研究以实现最佳管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uterine carcinosarcomas (UCS) represent a rare but aggressive subset of endometrial cancers, comprising <5% of uterine malignancies. To date, limited prospective trials exist from which evidence-based management of this rare malignancy can be developed. METHODS: The American Radium Society Appropriate Use Criteria presented in this manuscript are evidence-based guidelines developed by a multidisciplinary expert panel for management of women with UCS. An extensive analysis of current medical literature from peer-reviewed journals was performed. A well-established methodology (modified Delphi) was used to rate the appropriate use of imaging and treatment procedures for the management of UCS. These guidelines are intended for the use of all practitioners who desire information about the management of UCS. RESULTS: The majority of patients with UCS will present with advanced extra uterine disease, with 10% presenting with metastatic disease. They have worse survival outcomes when compared to uterine high-grade endometrioid adenocarcinomas. The primary treatment for non-metastatic UCS is complete surgical staging with total hysterectomy, salpingo-oophorectomy and lymph node staging. Patients with UCS appear to benefit from adjuvant multimodality therapy to reduce the chance of tumor recurrence with the potential to improve overall survival. CONCLUSION: Women diagnosed with uterine UCS should undergo complete surgical staging. Adjuvant multimodality therapies should be considered in the treatment of both early- and advanced stage patients. Long-term surveillance is indicated as many of these women may recur. Prospective clinical studies of women with UCS are necessary for optimal management.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Elshaikh MA, Modh A, Jhingran A, et al. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma. Gynecol Oncol. 2020. PMID: 32475772. doi:10.1016/j.ygyno.2020.04.683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。